Effect of felbamate on phenytoin and carbamazepine serum concentrations
| Autor: | Nina M. Graves, R. H. Fuerst, Ilo E. Leppik, Gregory B. Holmes |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Phenytoin
Adult Male Dose Adolescent medicine.medical_treatment Phenylcarbamates Pharmacology Felbamate Pharmacokinetics Double-Blind Method medicine Humans Drug Interactions Clinical Trials as Topic Epilepsy business.industry Carbamazepine Drug interaction Middle Aged United States Anticonvulsant Neurology Propylene Glycols Concomitant Anesthesia Anticonvulsants Drug Therapy Combination Female Neurology (clinical) business medicine.drug |
| Zdroj: | Epilepsia. 30(2) |
| ISSN: | 0013-9580 |
| Popis: | Felbamate (FBM) is a novel antiepileptic drug (AED) undergoing clinical trials in the United States. During a double-blind, cross-over clinical trial, patients received concomitant phenytoin (PHT) and carbamazepine (CBZ). Dosages of PHT and CBZ were adjusted to maintain serum concentrations +/- 20 and +/- 25% of baseline values. All patients required a PHT dosage decrease of 10-30% during active FBM treatment to maintain stable concentrations. CBZ serum concentrations decreased significantly in patients receiving active FBM. The mean decrease was 1.3 micrograms/ml and occurred in 30 of 32 patients. Therefore, FBM apparently causes a bidirectional effect on the serum concentrations of PHT and CBZ when all three drugs are taken concomitantly. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text